Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

Globus Medical’s first quarter of 2025 proved challenging, with results falling below expectations. The company attributed this underperformance to delays in Enabling Technology deals ...

Globus Medical, Inc. has a 1 year low of $54.48 and a 1 year high of $94.93. The firm has a 50 day moving average price of $69.35 and a 200 day moving average price of $78.83.

Globus Medical’s first quarter of 2025 proved challenging, with results falling below expectations. The company attributed this underperformance to delays in Enabling Technology deals, temporary ...

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised ...

Chester County Futures (CCF), in collaboration with Globus Medical, recently provided a transformative learning experience ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the“Company ...